Research Topics
| Andrea De LucaSummaryAffiliation: Catholic University Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1Carmela Pinnetti
Department of Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 15:127-9. 2010..The analysis of darunavir/ritonavir concentrations in peripheral maternal plasma throughout pregnancy, as well as in umbilical cord blood at delivery, showed low levels of darunavir in the mother and limited transfer across the placenta...- Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approachDimitrios Paraskevis
Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
Retrovirology 6:49. 2009..However the spatial diffusion of the epidemic from the perspective of the virus has not previously been traced... - Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTICarlo Torti
University of Brescia, Italy
BMC Infect Dis 11:23. 2011..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce... - Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosineAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
J Infect Dis 196:1645-53. 2007..Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed... - Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failureAndrea De Luca
Institute of Clinical Infectious Diseases, Policlinoco Universitario Agostino Gemelli, Catholic University of the Sacred Heart, Largo F Vito 1, 00168 Rome, Italy
J Acquir Immune Defic Syndr 45:411-7. 2007..The extent to which HIV-1 replication capacity (RC) influences the response to therapy remains to be established... - Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparisonAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
Antivir Ther 11:609-18. 2006..A multi-cohort prospective observational comparative study was performed... - Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testingAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Tor Vergata University, Rome, Italy
Curr Opin Infect Dis 16:573-80. 2003.... - Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistanceAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
J Infect Dis 187:1934-43. 2003..GSSs predicted changes in HIV RNA levels better in adherent patients than in nonadherent individuals. Interpretation may be improved, and knowledge should be used uniformly throughout different expert systems... - Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysisAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Lazio Region, Rome, Italy
AIDS 22:1759-67. 2008..To establish the effectiveness of cidofovir for AIDS-related progressive multifocal leukoencephalopathy (PML) in patients concomitantly receiving combination antiretroviral therapy... - Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomesAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 9:583-93. 2004.... - Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systemsAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 9:743-52. 2004..This work was presented in part at the First European Workshop on HIV Drug Resistance. Luxembourg, 4-6 March 2003 (Abstract 44); and at the 9th European Conference on CIinical AIDS Therapy. Warsaw, 25-28 October 2003 (Abstract F6/7)... - Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trialAndrea De Luca
Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
Antivir Ther 11:321-7. 2006.... - Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjectsAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
Arch Intern Med 162:2125-32. 2002..The effect of chronic coinfection with hepatitis viruses on the response to therapy against human immunodeficiency virus 1 (HIV-1) remains debated... - Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapyAndrea De Luca
Clinical Infectious Diseases, Catholic University, Rome, Italy
J Infect Dis 193:1219-22. 2006..42 [95% CI, 1.05-1.99]), use of nevirapine (adjusted OR, 1.60 [95% CI, 1.14-2.24]), use of efavirenz (adjusted OR, 1.56 [95% CI, 1.08-2.27]), and use of ritonavir (adjusted OR, 1.35 [95% CI, 1.04-1.75])... - Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available optionsAndrea De Luca
Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
Curr Opin HIV AIDS 5:27-37. 2010..Knowledge of the prevalence of transmitted and emerging drug resistance as well as its specific patterns is of help in guiding the selection of appropriate ART types and sequencing strategies... - Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new scoreAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 16:489-97. 2011..There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir (DRV). We validated existing rules and a newly derived score... - Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort studySimona Di Giambenedetto
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 12:835-9. 2007..We explored the evolution of genotypic drug resistance prevalence in treatment-failing patients from 1999 to 2005 in a clinical cohort... - Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutationMauro Zaccarelli
National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
Antivir Ther 8:51-6. 2003..M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment... - Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutationAndrea Antinori
National Institute for Infectious Diseases L Spallanzani IRCCS, Roma, Italy
Antivir Ther 12:1175-83. 2007..The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined... - Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)Antonella Cingolani
Istituto di Clinica delle Malattie Infettive, , Largo Agostino Gemelli 8, 00168 Rome, Italy
AIDS 16:369-79. 2002..CONCLUSION: The virological benefit of genotype-guided treatment decisions in heavily pre-exposed patients was short term. Patients adherence and residual treatment options influenced outcomes... - Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individualsGiorgio Antonucci
National Institute of Infectious Diseases, L Spallanzani, Rome, Italy
Clin Infect Dis 40:e101-9. 2005..We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype... - Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1Laura Bracciale
Institute of Clinical of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
AIDS Res Hum Retroviruses 25:261-7. 2009..The achievement of virological suppression is a strong predictor of reduced clinical progression... - Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamicsAndrea De Luca
Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
J Acquir Immune Defic Syndr 35:359-66. 2004..When these drugs are coadministered, therapeutic drug monitoring should be employed and the IQ can be used to determine target drug levels... - Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictorsSimona Di Giambenedetto
Institute of Clinical Infectious DiseasesCatholic University, Rome, Italy
Scand J Infect Dis 39:813-8. 2007..In patients failing PIs, the interpretation of genotypic resistance to fosamprenavir may change considerably according to the different algorithms and in respect to the effect of pharmacokinetic boosting with ritonavir... - Interpretation systems for genotypic drug resistance of HIV-1Andrea De Luca
Istituto di Clinica delle Malattie Infettive, , Rome, Italy
Scand J Infect Dis Suppl 35:29-34. 2003..Importantly, only 8 systems were intended for clinical use and 5 of these had at least partially undergone clinical validation... - Clinical implications of HIV-1 drug resistance in the neurological compartmentAndrea Antinori
National Institute for Infectious Diseases 'Lazzaro Spallanzani, IRCCS, Rome, Italy
Scand J Infect Dis Suppl 35:41-4. 2003.... - Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?Laura Bracciale
Institute of Clinical Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
Antivir Ther 14:99-101. 2009.... - Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotypingMattia C F Prosperi
Infectious Diseases Clinic, Catholic University of Sacred Heart, Rome, Italy
Retrovirology 7:56. 2010..7% false positive rate cutoff were evaluated using viral DNA and RNA samples, compared against each other and ESTA, using Cohen's kappa, phylogenetic analysis, and area under the receiver operating characteristic (AUROC)... - Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosisAngela Marzocchetti
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
J Neurovirol 13:338-46. 2007..To analyze virological and immunological features of AIDS-related progressive multifocal leukoencepalophathy (PML) and their association to disease prognosis... - Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimensMaria Paola Trotta
Istituto Nazionale per le Malattie Infettive, L. Spallanzani IRCCS, Rome, Italy
AIDS 17:1099-102. 2003..By contrast, younger age, self-report of active drug use, fatigue or vomiting negatively affected adherence. Self-reported sexual dysfunction was significantly associated with non-adherence only in PI-treated individuals... - Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in ItalySimona Di Giambenedetto
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 14:359-69. 2009..This study aimed to examine the evolution of genotypic drug resistance prevalence in treatment-failing patients in the multicentre, Italian, Antiretroviral Resistance Cohort Analysis (ARCA)... - Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study groupValentina Svicher
Department of Experimental Medicine, University of Rome, Roma, Italy
New Microbiol 35:17-25. 2012..The DIVA study is aimed at setting up a standardized genotypic tropism-testing on proviral-DNA for the routine clinical diagnostic-laboratory... - Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practiceMattia C F Prosperi
Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
J Med Virol 82:1996-2003. 2010..Despite the likely differences in patient population and adherence, both the low rate of virological failure and the lack of development of LPV/rtv resistance documented in clinical trials are thus confirmed in clinical practice... - A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimenMattia C F Prosperi
Infectious Diseases Clinic, Catholic University of the Sacred Heart, Rome, Italy
BMC Med Inform Decis Mak 11:40. 2011..However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed... - Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interactionMassimiliano Fabbiani
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
Pharmacol Res 63:249-53. 2011..In conclusion, a potential drug interaction between darunavir and raltegravir was observed, although this did not seem virologically significant. For the distinct metabolic pathways of these drugs, its mechanism remains to be determined... - The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispeciesMattia C F Prosperi
Infectious Diseases Clinic, Catholic University of the Sacred Heart, Rome, Italy
PLoS ONE 5:e13619. 2010..We introduce the threshold bootstrap clustering (TBC), a new methodology for partitioning molecular sequences, that does not require a phylogenetic tree estimation... - Virologic correlates of adherence to antiretroviral medications and therapeutic failureCarlo Federico Perno
INMI L Spallanzani, Rome, Italy
J Acquir Immune Defic Syndr 31:S118-22. 2002.... - Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practiceMassimiliano Fabbiani
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
J Antimicrob Chemother 64:109-17. 2009.... - Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapyAngela Marzocchetti
Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Largo Gemelli, 8, 00168 Rome, Italy
J Clin Microbiol 43:4175-7. 2005..5% (95% confidence intervals of 42.1 to 72.9%) in the HAART era; the specificity remained unchanged. Predictors of failure to detect JCV DNA were exposure to HAART at disease onset and higher CD4 counts... - The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapyAngela Marzocchetti
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
AIDS Res Hum Retroviruses 27:1299-309. 2011..10; p=0.04). Knowledge of the effect of genetic determinants on dyslipidemia and lipodystrophy may prompt the investigation of potential pathogenetic mechanisms and might eventually be used for guiding individualized treatment decisions... - Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA)Andrea Antinori
Clinical Department, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS, Roma, Italy
J Neurovirol 9:47-53. 2003..The use of cidofovir showed a trend towards a reduced risk of death... - Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort studyMattia C F Prosperi
Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
J Antimicrob Chemother 66:1886-96. 2011.... - Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patientsAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University of of Sacred Heart, Rome, Italy
AIDS 18:1602-4. 2004..Female sex and HCV genotype predicted early virological responses. Results support the early treatment of HCV in co-infected individuals... - Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapyAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
J Acquir Immune Defic Syndr 59:113-20. 2012..63, P = 0.11; cause-specific aRR 5.27, P = 0.019) than those with haplogroup H. Mitochondrial haplogroups may explain part of the genetic predisposition to lipodystrophy during combination antiretroviral therapy... - Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virusStefano Aquaro
Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
J Med Virol 68:479-88. 2002..In conclusion, the long-term dynamics and the high cumulative virus production that characterize HIV-1 infection of macrophages underscore the peculiar role of these cells as a persistently infected reservoir of HIV... - Correlates of independent HIV-1 replication in the CNS and of its control by antiretroviralsAndrea De Luca
Istituto di Clinica delle Malattie Infettive, Universita Cattolica del S Cuore, Largo Francesco Vito, I 00168 Rome, Italy
Neurology 59:342-7. 2002..To investigate in detail factors associated with independent replication of HIV-1 in CNS, and to predict its therapeutic control... - Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimizationMattia C F Prosperi
Department of Computer Science and Automation, University of Roma Tre, Informa Contract Research Organisation, Infectious Disease Clinic, Catholic University of Sacred Heart, Rome, Italy
Bioinformatics 25:1040-7. 2009..For a set of widely used combination therapies, results were consistent with findings reported in literature and with estimates coming from analysis on a large retrospective data base (EuResist)... - Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordanceRita Murri
Clinica delle Malattie Infettive, Universita Cattolica del S Cuore, 00168 Rome, Italy
J Gen Intern Med 19:1104-10. 2004..To evaluate the rate of discordance between patients and physicians on adherence to highly active antiretroviral therapy (HAART) and identify factors related to discordance in these two assessments... - Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study GroupValentina Svicher
University of Rome Tor Vergata, Department of Experimental Medicine, Roma, Italy
New Microbiol 33:195-206. 2010..The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trofile (ESTA) as reference-assay... - Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patientsMassimiliano Fabbiani
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Largo F Vito 1, 00168 Rome, Italy
Vaccine 29:2836-9. 2011..These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients... - A novel methodology for large-scale phylogeny partitionMattia C F Prosperi
Clinic of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
Nat Commun 2:321. 2011..Our method takes an advantage of a flexible notion of transmission cluster and can become a general framework to analyse other epidemics... - Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCRCinzia Dello Russo
Institute of Pharmacology, Catholic University Medical School, Rome, Italy
Pharmacogenomics 12:567-76. 2011..A fast, sensitive and specific test for HLA-B*57:01 detection has been developed in the present study... - Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining ConditionAntonella Cingolani
Catholic University
Clin Infect Dis 54:853-61. 2012..It seems to be driven mainly by a delay in achieving viral suppression. Whether this may be due to interactions between antituberculosis drugs and antiretrovirals needs to be investigated... - Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120Lucia Lisi
Institute of Pharmacology, Catholic University Medical School, Rome, Italy
J Neurochem 120:106-14. 2012..In this experimental paradigm, maraviroc significantly increased microglial activation, thus suggesting that its chronic use can exacerbate neuronal pathology, especially in HIV-experienced patients with higher cerebral IFN? levels... - Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availabilityLeonardo Palombi
Department of Public Health, University Tor Vergata, Catholic University, Rome, Italy
Clin Infect Dis 48:115-122. 2009..Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortality and loss to follow-up. Switching to second-line regimens is often delayed because of limited access to laboratory monitoring... - An outbreak of HIV-1 subtype G among Italian injecting drug usersMassimo Ciccozzi
Epidemiology Unit, Department of Infectious, Parasite and Immune mediated Diseases, Istituto Superiore di Sanita, Rome, Italy
AIDS 21:1213-5. 2007..All G subtypes but one were found among IDU. The phylogenetic analysis indicated that the outbreak was of monophyletic origin and was caused by HIV-1 strains similar to those from western Africa... - Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan AfricaAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
J Acquir Immune Defic Syndr 59:236-44. 2012..We investigated the prognostic value of virological and immunological status 6 months after ART initiation with respect to death, loss to follow-up, and treatment switch... - The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypesDavid A van de Vijver
Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, G04-614, 3584 CX Utrecht, The Netherlands
J Acquir Immune Defic Syndr 41:352-60. 2006..Because of differences in minor protease substitutions, protease inhibitor resistance could be enhanced in particular subtypes once the relevant major substitutions are selected... - Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapyLaura Aian Gillini
J Acquir Immune Defic Syndr 29:546-7. 2002 - Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysisMassimo Puoti
Clinica di Malattie Infettive e Tropical, Universita degli Studi di Brescia, Brescia, Italy
Antivir Ther 11:567-74. 2006..The impact of lamivudine (3TC) as part of combination antiretroviral therapy (cART) on the risk of liver-related death (LRD) in HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively studied... - Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failureAndrea Antinori
Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
AIDS Res Hum Retroviruses 18:835-8. 2002..No virological response was observed in six patients harboring a single Y181C/I mutation. On the basis of the present data, sequential use of NNRTIs should be avoided in the management of treatment failure... - Effect of hepatitis C virus genotype on CD4+ T cell count in a cohort of antiretroviral-naive HIV-1-infected individualsGiorgio Antonucci
J Infect Dis 192:703-4; author reply 704-5. 2005 - Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive PatientsAntonella d'Arminio Monforte
Istituto di Malattie Infettive e Tropicali, Universita di Milano, Milano, Italy
J Acquir Immune Defic Syndr 38:407-16. 2005.... - Triple-nucleoside regimens versus efavirenzAndrea De Luca
N Engl J Med 351:717-9; author reply 717-9. 2004 - Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring systemRainer Ziermann
Bayer HealthCare LLC, Diagnostics Division, 800 Dwight Way, Berkeley, CA 94710, USA
J Clin Virol 31:S7-15. 2004..5, and VGI GuideLines Rules 4.0) were statistically significantly correlated with virologic therapy response as measured by viral load testing... - A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loadsAlessandro Cozzi-Lepri
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, United Kingdom
J Infect Dis 194:20-8. 2006.... - CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/lCristina Mussini
Clinic of Infectious and Tropical Diseases, Azienda Ospedaliero Universitaria Policlinico, University of Modena and Reggio Emilia, Via del Pozzo, 71, 41100 Modena, Italy
AIDS 19:287-94. 2005..Little is known about CD4 cell count changes in patients with high CD4 cell counts who interrupt antiretroviral therapy, especially in those with a nadir of 250-350 x 10 cells/l... - Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus WorkshopGiampiero Carosi
Department of Infectious Disease, University of Brescia, Brescia, Italy
AIDS Rev 7:161-7. 2005.... - Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitorsCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Piazzale Spedali Civili 1, 25123 Brescia, Italy
J Clin Virol 35:414-9. 2006..To determine the impact of genotypic inhibitory quotient (GIQ) for lopinavir (LPV) in patients failing HAART with limited antiretroviral exposure... - Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical managementAnnemarie M J Wensing
Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, The Netherlands
J Infect Dis 192:958-66. 2005..These data argue for testing all drug-naive patients and are of relevance when guidelines for management of postexposure prophylaxis and first-line therapy are updated... - A whole-genome association study of major determinants for host control of HIV-1Jacques Fellay
Center for Population Genomics and Pharmacogenetics, Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA
Science 317:944-7. 2007..These findings emphasize the importance of studying human genetic variation as a guide to combating infectious agents... - Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?Marco Bongiovanni
Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
Clin Infect Dis 45:650-3. 2007.... - A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patientsKristel Van Laethem
Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Belgium
Antivir Ther 7:123-9. 2002..However, it should be subject to regular updates as is needed in this fast developing field... - Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational studyCristina Mussini
Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Azienda Policlinico, Modena, Italy
Clin Infect Dis 38:565-71. 2004..Recurrent cryptococcal infection should be suspected in patients whose serum cryptococcal antigen test results revert back to positive after discontinuation of maintenance therapy... - Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in womenInmaculada Jarrin
National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
Am J Epidemiol 168:532-40. 2008..74, 95% CI: 0.56, 0.98). Sex differences in HIV disease progression have become larger and statistically significant in the era of highly active antiretroviral therapy, supporting a stronger impact of health interventions among women... - Changes in the risk of death after HIV seroconversion compared with mortality in the general populationKrishnan Bhaskaran
MRC Clinical Trials Unit, 222 Euston Rd, London NW1 2DA, United Kingdom
JAMA 300:51-9. 2008..Mortality among human immunodeficiency virus (HIV)-infected individuals has decreased dramatically in countries with good access to treatment and may now be close to mortality in the general uninfected population... - A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted RegiCarlo Torti
Institute for Infectious and Tropical Diseases, Brescia, Italy
Clin Infect Dis 40:1828-36. 2005.... - [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)]Patrizio Pezzotti
Reparto AIDS MST, Laboratorio di Epidemiologia e Biostatistica, Istituto Superiore di Sanita, Roma
Epidemiol Prev 27:348-55. 2003..6 (95% CI +34.1; +45.1)per year. This study provides strong evidence that the efficacy of the HAART estimated in the controlled clinical trials has resulted in a real reduction at the population level of morbidity and mortality... - Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrationsCarlo Torti
J Acquir Immune Defic Syndr 35:324-6. 2004 - The influence of hepatitis C virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1-infected patients after initiation of highly active antiretroviral therapySimona Di Giambenedetto
J Acquir Immune Defic Syndr 36:641-2. 2004 - Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study GroupCristina Mussini
Clinic of Infectious and Tropical Diseases, Azienda Ospedaliera Policlinico, University of Modena and Reggio Emilia, Modena, Italy
Clin Infect Dis 36:645-51. 2003..Patients who present with symptoms after discontinuation of secondary prophylaxis should be evaluated for PCP despite high CD4 count and complete virus suppression...